Results 141 to 150 of about 2,807 (168)

Image Guided Intensive Modulated Radiosurgery Boost Combined with Conformal Radiotherapy Prostate Cancer Patients

International Journal of Radiation Oncology*Biology*Physics, 2009
M. Wojciech, H. Urbanczyk, L. Hawrylewicz, L. Misztal, I. Wesołowska, W. Leszczynski, J. Rembak-Szynkiewicz, J. Ciechowicz, K. Slosarek, L. Miszczyk   +9 more
openaire   +1 more source

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Lancet, The, 2021
Denis Y Logunov, Inna V Dolzhikova, Dmitry V Shcheblyakov   +2 more
exaly  

INCATE: a partnership to boost the antibiotic pipeline

Nature Reviews Drug Discovery, 2022
exaly  

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

Lancet, The, 2023
exaly  

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Lancet, The, 2020
Maheshi N Ramasamy, Pedro M Folegatti, Daniel R Owens   +2 more
exaly  

A Phase II Prospective Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

International Journal of Radiation Oncology*Biology*Physics, 2009
K. Beal, K. Chan, T. Chan, Y. Yamada, A. Narayana, S. Lymberis, P. Gutin, V. Tabar, C. Brennan   +8 more
openaire   +1 more source

Surgery Followed by Radiosurgery Boost for Metastases

2014
openaire   +1 more source

Using immunotherapy to boost the abscopal effect

Nature Reviews Cancer, 2018
Wilfred Ngwa, Jonathan D Schoenfeld, Sandra Demaria   +2 more
exaly  

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

Lancet, The, 2004
David W Andrews, Minesh P Mehta
exaly  

Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?

Lancet, The, 2023
exaly